Ruxolitinib cream shows promise for vitiligo in phase III trials

In TRuE-V1 and TRuE-V2 studies (n ≤ 600), patients on this topical JAK inhibitor therapy had statistically significant ≥75% improvement in facial vitiligo area scoring at week 24 from baseline vs vehicle control (p<0.0001). Regulatory submissions to FDA & EMA planned in late 2021

Source:

Biospace Inc.